BTK Inhibitor TQB3702 clinical trials
How each study uses BTK Inhibitor TQB3702 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the BTK Inhibitor TQB3702 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- TQB3702 tablets
- 4
Studies by the year they started
4 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test BTK Inhibitor TQB3702.
- Dec 2026Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)Phase 2 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Studies
Open first, then newest update. How each study uses BTK Inhibitor TQB3702 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)Not yet recruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06859931Written as TQB3702 Tablets
- A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult SubjectsRecruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06448273Written as TQB3702 tablets
- A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic MalignancyNot yet recruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06211751Written as TQB3702 tablets
- Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor SubjectsStatus unknownPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05610202Written as TQB3702 tablets